16/11/2023 - Vertex Pharmaceuticals Incorporated: Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Attachments

• Original Link
• Original Document
• Permalink

Disclaimer

Vertex Pharmaceuticals Incorporated published this content on 16 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 November 2023 06:52:13 UTC.